An observational study in Hypertrophic Scars and Keloids, sponsored by Hanson Medical, Inc.. Not yet recruiting. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Hanson Medical, Inc. · Observational
The purpose of this PMCF investigation is to determine whether there are differences between the two formulations (Dermatix and Dermatix Ultra) in improving keloid and hypertrophic scars clinical symptoms and in the overall scar perception (including scar appearance and treatment perception).
This PMCF investigation has been designed to address the conclusions of the latest CER [PDPROJ-4-CE-R] and the objectives. It has been chosen as an appropriate activity as it enables the collection of device-specific data on both device formulations and on the entire intended population. Moreover, the design of the PMCF investigation (single-center, parallel, open-label, two-arm, randomized controlled study) enables the direct comparison of the clinical performance/benefit between the two formulations.
129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.
This study's planned enrollment of 150 is above the median of 30 across 13 observational studies indexed under Cicatrix, Hypertrophic.
Browse Cicatrix, Hypertrophic studies →This is the only study on the registry with Hanson Medical, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The total number of subjects will be 75 per arm (150 total). However, to allow for potential dropouts and protocol deviations, the planned enrolment will be increased by approximately 10%, yielding a total of 84 per arm (168 total).
To ensure that both treatment groups include patients with (a) scars at risk of developing hypertrophic or keloid scars (i.e., recent scars) and (b) pre-existing hypertrophic or keloid scars (i.e., older scars), a stratified randomization procedure will be used. This approach will evenly distribute the proportion of older scars and recent scars between the two groups based on the estimated prevalence of pathological scars in the overall scar population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients at risk of developing a hypertrophic or keloid scar, aged 3 years and older.
Device: Dermatix · Device: Dermatix Ultra
Patients with existing scars, aged 3 years and older,
Device: Dermatix · Device: Dermatix Ultra
Patients will be supplied with two 15g tubes of Dermatix at Visit 1 - Baseline Visit with the clinician, which will be sufficient to last the duration of the study (6-months) when applied as instructed (i.e. twice daily). If for any reason the patient runs out of the investigational product, a contingency supply will be in place and patients will be supplied with an additional tube. Patients will also be provided with the IFU of the supplied device and the clinician will provide instructions as to the application, frequency, and duration of use of the device (i.e. applied topically to the scar, twice daily for 6 months/until final study visit).
Patients will be supplied with two 15g tubes of Dermatix Ultra at Visit 1 - Baseline Visit with the clinician, which will be sufficient to last the duration of the study (6-months) when applied as instructed (i.e. twice daily). If for any reason the patient runs out of the investigational product, a contingency supply will be in place and patients will be supplied with an additional tube. Patients will also be provided with the IFU of the supplied device and the clinician will provide instructions as to the application, frequency, and duration of use of the device (i.e. applied topically to the scar, twice daily for 6 months/until final study visit).
Vancouver Scar Scale (VSS)
Comparison of clinical symptoms and scar appearance between Dermatix and Dermatix Ultra (between the two study arms) using the Vancouver Scar Scale (VSS), i.e., * scar pigmentation * scar vascularity * scar pliability/elasticity * scar height * scar itchiness * scar pain
Time frame: 6 months of treatment
Satisfaction, Change from Baseline, Complications
* Comparison of treatment satisfaction between Dermatix and Dermatix Ultra (between arms) after using a 5-point Likert scale to rate the treatment satisfaction as: 1. unsatisfactory 2. moderate 3. good 4. very good 5. excellent * Change from baseline (within arms) of clinical symptoms and scar appearance using the VSS, i.e., * scar pigmentation * scar vascularity * scar pliability/elasticity * scar height * scar itchiness * scar pain * The incidence of all complications during the study period, including: * Adverse Events (AE) * Serious Adverse Events (SAEs), * Serious Adverse Device Effects (SADE), * Unanticipated Serious Adverse Device Effect (USADE).
Time frame: 6 months of treatment
No study locations are listed for this record.
Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.